Your browser doesn't support javascript.
loading
Body dysmorphia in common skin diseases: results of an observational, cross-sectional multicentre study among dermatological outpatients in 17 European countries.
Schut, Christina; Dalgard, Florence J; Bewley, Anthony; Evers, Andrea W M; Gieler, Uwe; Lien, Lars; Sampogna, Francesca; Ständer, Sonja; Tomás-Aragonés, Lucía; Vulink, Nienke; Finlay, Andrew Y; Legat, Franz J; Titeca, Geraldine; Jemec, Gregor B; Misery, Laurent; Szabó, Csanád; Grivcheva-Panovska, Vesna; Spillekom-van Koulil, Saskia; Balieva, Flora; Szepietowski, Jacek C; Reich, Adam; Roque Ferreira, Bárbara; Lvov, Andrey; Romanov, Dmitry; Marron, Servando E; Gracia-Cazaña, Tamara; Svensson, Ake; Altunay, Ilknur K; Thompson, Andrew R; Zeidler, Claudia; Kupfer, Joerg.
Afiliação
  • Schut C; Institute of Medical Psychology, Justus-Liebig-University, Gießen, Germany.
  • Dalgard FJ; Division of Mental Health and Addiction, Vestfold Hospital Trust, Tønsberg, Norway.
  • Bewley A; Department of Dermatology and Venereology, Skåne University Hospital, Malmo, Sweden.
  • Evers AWM; Barts Health NHS Trust & Queen Mary University of London, London, UK.
  • Gieler U; Health, Medical and Neuropsychology Department, Leiden University, Leiden, the Netherlands.
  • Lien L; Vitos Klinik, Gießen, Germany.
  • Sampogna F; Faculty of Social and Health Sciences, Inland Norway University of Applied Sciences, Elverum, Norway.
  • Ständer S; Norwegian National Advisory Unit on Concurrent Substance Abuse and Mental Health Disorders, Innlandet Hospital Trust, Brumunddal, Norway.
  • Tomás-Aragonés L; Clinical Epidemiology Unit, IDI-IRCCS, Rome, Italy.
  • Vulink N; Department of Dermatology and Centre for Chronic Pruritus, University Hospital Münster, Münster, Germany.
  • Finlay AY; Department of Psychology, University of Zaragoza, Zaragoza, Spain.
  • Legat FJ; Aragon Psychodermatology Research Group Zaragoza, Zaragoza, Spain.
  • Titeca G; Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.
  • Jemec GB; Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.
  • Misery L; Department of Dermatology, Medical University of Graz, Graz, Austria.
  • Szabó C; Clinique Notre Dame de Grâce, Gosselies, Belgium.
  • Grivcheva-Panovska V; Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
  • Spillekom-van Koulil S; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Balieva F; Department of Dermatology, University Hospital of Brest, Brest, France.
  • Szepietowski JC; Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
  • Reich A; University St Cyril and Methodius, School of Medicine, PHI University Clinic of Dermatology, Skopje, North Macedonia.
  • Roque Ferreira B; Radboud Institute for Health Sciences, Department of Medical Psychology, Radboud University Medical Centre, Nijmegen, the Netherlands.
  • Lvov A; Department of Dermatology, Stavanger University Hospital, Stavanger, Norway.
  • Romanov D; Faculty of Health Sciences, University of Stavanger, Stavanger, Norway.
  • Marron SE; Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.
  • Gracia-Cazaña T; Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszów University, Rzeszów, Poland.
  • Svensson A; Centre for Philosophy of Science of the University of Lisbon, Lisbon, Portugal.
  • Altunay IK; Department of Dermatology, Centre Hospitalier de Mouscron, Mouscron, Belgium.
  • Thompson AR; University of Brest, Lien, France.
  • Zeidler C; Central State Medical Academy of Department of Presidential Affairs, Moscow, Russia.
  • Kupfer J; Medical Research and Educational Centre, Lomonosov Moscow State University, Moscow, Russia.
Br J Dermatol ; 187(1): 115-125, 2022 07.
Article em En | MEDLINE | ID: mdl-35041211
ABSTRACT

BACKGROUND:

Body dysmorphic disorder (BDD) is a common psychiatric disorder associated with high costs for healthcare systems as patients may repeatedly ask for different, often not effective, interventions. BDD symptoms are more prevalent in patients with dermatological conditions than in the general population, but there are no large sample studies comparing the prevalence of BDD symptoms between patients with dermatological conditions and healthy skin controls.

OBJECTIVES:

To compare the prevalence of BDD symptoms between patients with different dermatological conditions and healthy skin controls and to describe sociodemographic, physical and psychological factors associated with BDD symptoms to identify patients who may have a particularly high chance of having this condition.

METHODS:

This observational, cross-sectional, comparative multicentre study included 8295

participants:

5487 consecutive patients with different skin diseases (56% female) recruited among dermatological outpatients at 22 clinics in 17 European countries, and 2808 healthy skin controls (66% female). BDD symptoms were assessed by the Dysmorphic Concern Questionnaire. Sociodemographic data and information on psychological factors and physical conditions were collected. Each patient was given a dermatological diagnosis according to ICD-10 by a dermatologist. The study was registered with number DRKS00012745.

RESULTS:

The average participation rate of invited dermatological patients was 82.4% across all centres. BDD symptoms were five times more prevalent in patients with dermatological conditions than in healthy skin controls (10.5% vs. 2.1%). Patients with hyperhidrosis, alopecia and vitiligo had a more than 11-fold increased chance (adjusted Odds Ratio (OR) > 11) of having BDD symptoms compared with healthy skin controls, and patients with atopic dermatitis, psoriasis, acne, hidradenitis suppurativa, prurigo and bullous diseases had a more than sixfold increased chance (adjusted OR > 6) of having BDD symptoms. Using a logistic regression model, BDD symptoms were significantly related to lower age, female sex, higher psychological stress and feelings of stigmatization.

CONCLUSIONS:

Clinical BDD symptoms are significantly associated with common dermatological diseases. As such symptoms are associated with higher levels of psychological distress and multiple unhelpful consultations, general practitioners and dermatologists should consider BDD and refer patients when identified to an appropriate service for BDD screening and management.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Acne Vulgar / Transtornos Dismórficos Corporais Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Acne Vulgar / Transtornos Dismórficos Corporais Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article